Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics confirmed launch readiness for veligrotug, which has a PDUFA target action date of June 30, 2026, and reported positive topline data from the REVEAL-1 and REVEAL-2 Phase 3 trials for subcutaneous elegrobart. Q1 financial results showed a net loss of $104.9 million, with R&D expenses of $77.6 million and SG&A expenses rising to $38.7 million due to commercial launch preparations.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.